secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEXGEL, INC. (NXGL)
CIK:        0001468929
Form:       8-K
Filed at:   2026-05-12T20:30:25+00:00
Accession:  0001493152-26-022503
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NEXGEL appoints two Sequence LifeScience leaders to board; Sequence led $5.5M financing
--------------------------------------------------------------------------------

- Brian J. Kieser (CEO) and Kevin M. Harris (COO) of Sequence LifeScience appointed to NEXGEL board effective May 6, 2026.
- Sequence led $5.5M convertible note financing ($0.60/ share conversion, $0.80 warrant) to close Celularity acquisition.
- Kieser individually issued $1M convertible note (same terms: $0.60 conversion, $0.80 warrant) on May 11, 2026.
- Kieser is indirect sole owner of Sequence; Harris is COO with no equity in Sequence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468929/000149315226022503/0001493152-26-022503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468929/000149315226022503/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer